Adjuvant endocrine therapy – Timing #2
In patients with ER-positive tumours who do not commence adjuvant endocrine therapy immediately after surgery or chemotherapy, delayed endocrine therapy is still clinically beneficial.
In patients with ER+ tumours who do not receive adjuvant endocrine therapy immediately after surgery or chemotherapy, delayed endocrine therapy is still clinically beneficial
How this guidance was developed
This recommendation was adopted from the CCO 2014 guidelines (Canada). The source recommendation was based on a systematic review of the evidence conducted to March 2012 and was not graded by the source guideline authors. The source recommendation was accepted with minor stylistic changes, but with no change to the meaning or tone of the source recommendation.
Adjuvant endocrine therapy – Timing #2
In patients with ER-positive tumours who do not commence adjuvant endocrine therapy immediately after surgery or chemotherapy, delayed endocrine therapy is still clinically beneficial.
This recommendation was adopted from the CCO 2014 guidelines (Canada). The source recommendation was based on a systematic review of the evidence conducted to March 2012 and was not graded by the source guideline authors. The source recommendation was accepted with minor stylistic changes, but with no change to the meaning or tone of the source recommendation.